Perelman School of Medicine at the University of Pennsylvania
Drug is the first to target common mutation associated with relapse and short survival in AML
We’ve updated our Privacy Policy to make it clearer how we use your personal data. Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.